Content about GPhA

May 13, 2013
GPhA promotes lobbyist

The Generic Pharmaceutical Association has promoted Jason Money to associate VP federal government affairs, the trade group said Monday.

WASHINGTON — The Generic Pharmaceutical Association has promoted Jason Money to associate VP federal government affairs, the trade group said Monday.

Money, who has worked for the GPhA for six years, was previously the organization's senior director for federal affairs. In the new position, he will continue lobbying on behalf of the generic drug industry in Congress.

March 5, 2013
GPhA defends patent settlements as Supreme Court date nears

The stakes are high in a case involving generic drug maker Actavis and the Federal Trade Commission that will soon go before the Supreme Court, the head of a generic drug industry lobbying group said in a conference call with reporters Tuesday.

NEW YORK — The stakes are high in a case involving generic drug maker Actavis and the Federal Trade Commission that will soon go before the Supreme Court, the head of a generic drug industry lobbying group said in a conference call with reporters Tuesday.

The case, FTC v. Actavis, will go before the high court on March 25 and may decide the future of patent settlements between branded and generic drug companies. The Generic Pharmaceutical Association filed an amicus brief with the court last week defending the settlements as beneficial to consumers.

February 21, 2013
GPhA appoints board of directors for 2013

The Generic Pharmaceutical Association re-elected its chairman from last year and appointed a new board of directors for 2013 whose members run from A to Z — as in Amneal to Zydus.

ORLANDO, Fla. — The Generic Pharmaceutical Association re-elected its chairman from last year and appointed a new board of directors for 2013 whose members run from A to Z — as in Amneal to Zydus.

"We are grateful for the vision and support of the 2012 board of directors, and we are excited to move ahead with our chairman and our 2013 board," GPhA president and CEO Ralph Neas said. "In a time of enormous change and growth for our industry, leadership is critical."

February 13, 2013
State of the Union address draws mixed responses from drug industry

Some people liked President Barack Obama's State of the Union address Tuesday night, and some people didn't, and the response from the drug industry was no less mixed.

WASHINGTON — Some people liked President Barack Obama's State of the Union address Tuesday night, and some people didn't, and the response from the drug industry was no less mixed.

The Generic Pharmaceutical Association called for measures to lower healthcare costs, including ensuring that generic pharmaceuticals and biosimilars reach patients' hands quickly and also avoiding measures intended to provide savings that the GPhA said would raise prescription drug costs, though the grow didn't specify what those measures were.

November 5, 2012
NewsBytes — Chain Pharmacy, 11/5/12

The Food and Drug Administration has approved a generic drug for treating blood pressure and chest pain.

FDA approves cardiovascular drug

MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic drug for treating blood pressure and chest pain. Actavis announced the approval of diltiazem hydrochloride extended-release capsules.
The drug is a generic version of Valeant’s Tiazac. The branded drug and its generic equivalents had sales of about $76.3 million in 2011, according to IMS Health.



October 10, 2012
GPhA appoints CVS Caremark public policy director

An executive from CVS Caremark will guide policy for a generic drug industry trade association.

WASHINGTON — An executive from CVS Caremark will guide policy for a generic drug industry trade association.

The Generic Pharmaceutical Association said Wednesday that it had appointed CVS Caremark senior director of public policy Christine Simmon to run its policy shop as SVP policy and strategic alliances, effective Oct. 24. Christine Simmon previously worked for the GPhA as VP policy, public affairs and development from 2002 to 2006.

August 17, 2012
Generics offer affordability for specialty Rx

The U.S. healthcare system presents a paradox: It’s the most expensive system in the world, and yet it produces among the worst results among developed countries.

The U.S. healthcare system presents a paradox: It’s the most expensive system in the world, and yet it produces among the worst results among developed countries. According to the most recent report from the National Health Expenditure Accounts, spending on health care reached $2.6 trillion in 2010, or more than $8,400 per person and around 18% of the country’s gross domestic product.


April 19, 2012
GPhA signs on with IMS Health to address drug shortages

A trade organization representing generic drug manufacturers announced Thursday its latest solution to the problem of drug shortages.

WASHINGTON — A trade organization representing generic drug manufacturers announced Thursday its latest solution to the problem of drug shortages.

February 24, 2012
Hospira joins GPhA

Generic drug maker Hospira has joined the country's largest lobby for the generic drug industry, the company said.

LAKE FOREST, Ill. — Generic drug maker Hospira has joined the country's largest lobby for the generic drug industry, the company said.

Hospira, which specializes in generic injectables and infusion technology, announced that it had joined the Generic Pharmaceutical Association. In addition to generic pharmaceuticals, the company also makes biosimilars for the European market.

November 15, 2011
GPhA urges congressional super committee not to ban patent settlements

The generic drug lobby is stepping up its efforts to persuade the congressional super committee to avoid adopting rules that would ban some patent settlements between branded and generic drug makers.

WASHINGTON — The generic drug lobby is stepping up its efforts to persuade the congressional super committee to avoid adopting rules that would ban some patent settlements between branded and generic drug makers.

October 28, 2011
GPhA shows support for National Prescription Drug Take-Back Day

Saturday is the Drug Enforcement Administration's National Prescription Drug Take-Back Day, and the country's largest lobbying group representing the generic drug industry is expressing its support.

WASHINGTON — Saturday is the Drug Enforcement Administration's National Prescription Drug Take-Back Day, and the country's largest lobbying group representing the generic drug industry is expressing its support.

September 12, 2011
ReportersNotebook — Chain Pharmacy, 9/19/11

The Generic Pharmaceutical Association has named Ralph Neas as its new president and CEO.

EXECUTIVE NEWS — The Generic Pharmaceutical Association has named Ralph Neas as its new president and CEO. Neas, currently president and CEO of the National Coalition on Health Care, replaces Kathleen Jaeger, who stepped down as president and CEO of GPhA in May 2010 after eight years with the organization. The GPhA said it planned to spend September introducing Neas to stakeholders in a broad outreach effort.


September 7, 2011
GPhA names new president and CEO

The Generic Pharmaceutical Association has named Ralph Neas as its new president and CEO, the group said Wednesday.

WASHINGTON — The Generic Pharmaceutical Association has named Ralph Neas as its new president and CEO, the group said Wednesday.

Neas, currently president and CEO of the National Coalition on Health Care, replaces Kathleen Jaeger, who stepped down as president and CEO of GPhA in May 2010 after eight years with the organization. The GPhA said it planned to spend September introducing Neas to stakeholders in a broad outreach effort.

February 3, 2011
Former NCPA executive joins GPhA

The former top executive of the Generic Pharmaceutical Association may have gone to work for the National Community Pharmacists Association, but the generic drug industry trade group got one of the independent pharmacy group’s executives as well.

WASHINGTON — The former top executive of the Generic Pharmaceutical Association may have gone to work for the National Community Pharmacists Association, but the generic drug industry trade group got one of the independent pharmacy group’s executives as well.

February 1, 2011
Biosimilars regulations 
unlikely to unfold soon

As soon as members of Congress took their seats last month, the new Republican majority announced it would make good on its pledge to repeal the Patient Protection and Affordable Care Act. The effort largely is symbolic and unlikely to succeed, so at least one portion of the healthcare-reform law will likely remain in effect, namely the abbreviated approval pathway for follow-on biologics, also known as the Biologics Price Competition and Innovation Act.


February 21, 2010
Watson CEO to serve as GPhA chairman

Watson Pharmaceuticals president and CEO Paul Bisaro will serve as the Generic Pharmaceutical Association’s chairman...